Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 85
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT03813186 | Effect of Food on Blood Levels of ASTX727 | ||
| NCT00005873 | Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer | ||
| NCT05360160 | A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) | ||
| NCT01685268 | A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate | ||
| NCT06297629 | A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation | ||
| NCT00113256 | Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer | ||
| NCT05082259 | ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab | ||
| NCT00005871 | Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer | ||
| NCT03603964 | Guadecitabine Extension Study | ||
| NCT00254163 | Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients | ||
| NCT04250246 | A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 | ||
| NCT04155580 | A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) | ||
| NCT03913455 | Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer | ||
| NCT01183949 | Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma | ||
| NCT00005877 | Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer | ||
| NCT00042003 | Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec) | ||
| NCT02907359 | Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs | ||
| NCT00041990 | Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec) | ||
| NCT03075826 | A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms | ||
| NCT00005876 | Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery | ||
| NCT04637009 | A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms | ||
| NCT00894894 | Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies | ||
| NCT00504205 | MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma | ||
| NCT01294202 | A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST | ||
| NCT01896856 | Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer | ||
| NCT00005870 | Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas | ||
| NCT05007873 | ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase | ||
| NCT02998567 | Combination Study of Guadecitabine/ASTX727 and Pembrolizumab | ||
| NCT03922555 | ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas | ||
| NCT01696032 | SGI-110 in Combination With Carboplatin in Ovarian Cancer | ||
| NCT00006047 | Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide | ||
| NCT01652144 | A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma | ||
| NCT00113113 | Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction | ||
| NCT04655755 | Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | ||
| NCT01239108 | Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias | ||
| NCT01712217 | A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib | ||
| NCT02901899 | Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | ||
| NCT00453193 | Alemtuzumab and Pentostatin In T-cell Neoplasms | ||
| NCT02348489 | SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction | ||
| NCT00878423 | Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors | ||
| NCT04953923 | Thorough QT Assessment of Cedazuridine in Healthy Subjects | ||
| NCT00131313 | Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. | ||
| NCT00005874 | Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas | ||
| NCT03875287 | Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors | ||
| NCT04134884 | Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer | ||
| NCT02608437 | A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients | ||
| NCT03576963 | Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | ||
| NCT01261312 | SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) | ||
| NCT00496873 | Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan | ||
| NCT02103478 | Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) |
